Christopher D Lao MD MPH

Oncology•Ann Arbor, MI

Hematologic Oncology, Melanoma

Professor, Internal Medicine, University of Michigan Medical School

Join to View Full Profile

1500 East Medical Center DrB1 floor Cancer Recp CAnn Arbor, MI 48109
Phone+1 734-647-8906

Education & Training

University of MichiganFellowship, Hematology and Medical Oncology, 2001 - 2004
University of Alabama Medical CenterResidency, Internal Medicine, 1998 - 2001
Icahn School of Medicine at Mount SinaiClass of 1998

Certifications & Licensure

MI State Medical License 2001 - 2026
AL State Medical License 1999 - 2001

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013

Clinical Trials

Dinaciclib in Treating Patients With Stage IV Melanoma Start of enrollment: 2009 Jul 01
ACTIVE_NOT_RECRUITING
PHASE2
PROCLAIM Registry to Evaluate the Treatment Patterns and Clinical Response in Malignancy Start of enrollment: 2011 Aug 01
Completed
HD IL-2 + Vemurafenib in Patients With BRAF Mutation Positive Metastatic Melanoma Start of enrollment: 2012 Aug 01
Terminated
Phase 4
Molecularly Targeted Therapy in Treating Patients With BRAF Wild-type Melanoma That is Metastatic Start of enrollment: 2014 May 01
Completed
Phase 2
Ipilimumab Induction in Patients With Melanoma Brain Metastases Receiving Stereotactic Radiosurgery Start of enrollment: 2014 Apr 01
Terminated
Phase 2
Dabrafenib and Trametinib for the Treatment of Patients With Stage III-IV BRAF Mutant Melanoma That Cannot Be Removed by Surgery Start of enrollment: 2014 Sep 19
ACTIVE_NOT_RECRUITING
PHASE2
A Study of Relatlimab Plus Nivolumab Versus Nivolumab Alone in Participants With Advanced Melanoma Start of enrollment: 2018 Apr 11
ACTIVE_NOT_RECRUITING
PHASE2, PHASE3
A Study to Assess Safety of Relatlimab With Ipilimumab in Participants With Advanced Melanoma Who Progressed on Anti-Programmed Cell Death Protein 1 (Anti-PD-1) Treatment Start of enrollment: 2021 Dec 09
TERMINATED
PHASE1
Intestinal Microbiome Modification With Resistant Starch in Patients Treated With Dual Immune Checkpoint Inhibitors Start of enrollment: 2021 Jun 02
Completed
Early Phase 1
Join now to see all

Publications & Presentations

PubMed

Comparative Analysis of Intracranial Response Assessment Criteria in Patients With Melanoma Brain Metastases Treated With Combination Nivolumab + Ipilimumab in CheckMa...
Raymond Y Huang, Gilbert Youssef, Thomas Nelson, Patrick Y Wen, Peter Forsyth
Journal of Clinical Oncology. 2025-04-01
Nivolumab With or Without Ipilimumab in Patients With Recurrent or Metastatic Merkel Cell Carcinoma: A Nonrandomized, Open-Label, International, Multicenter Phase I/II...
Shailender Bhatia, Suzanne L Topalian, William Sharfman, Tim Meyer, Neil Steven
Journal of Clinical Oncology. 2025-03-20
2 citations
Pooled Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone in Patients With Advanced Melanoma.
Georgina V Long, James Larkin, Dirk Schadendorf, Jean-Jacques Grob, Christopher D Lao
Journal of Clinical Oncology. 2025-03-10

Journal Articles

Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain
Kim Margolin, Omid Hamid, Christopher D Lao, Anna C Pavlick, Michael A Postow, F Stephen Hodi, Nikhil I Khushalani, Marc S Ernstoff, Hussein A Tawbi, Igor Puzanov, Ahm..., The New England Journal of Medicine

Grant Support

Development Of A Melanoma Chemoprevention ModelNational Cancer Institute2006–2010
Phase I Single-Dose Safety And Pharmacokinetics Clinical Study Of ResveratrolNational Center For Research Resources2005–2006
Feasibility Of Barrett?S Esophagus Chemoprev Through Eval Of Esophageal ResectNational Center For Research Resources2005

Professional Memberships

American Society of Clinical Oncology - ASCO
Member